- 825–836. doi:10.1016/s0091-3057(01)00669-4. PMID 11888573.
Costa G,
Gołembiowska K (January 2022). "Neurotoxicity of MDMA: Main
effects and mechanisms"...
- Lett. 170 (1): 75–82. doi:10.1016/j.toxlet.2007.02.007. PMID 17382495.
Gołembiowska,
Krystyna (2022). "Pharmacology and
Neurotoxicity of 5-MeO-DIPT". Handbook...
- "PDSP Database". UNC (in Zulu).
Retrieved September 5, 2024.
Wojtas A,
Gołembiowska K (December 2023). "Molecular and
Medical Aspects of Psychedelics". Int...
- 287–293. doi:10.3390/psychoactives2040018. ISSN 2813-1851.
Wojtas A,
Gołembiowska K (December 2023). "Molecular and
Medical Aspects of Psychedelics". Int...
-
Retrieved 2024-01-23.
Herian M,
Wojtas A, Kamińska K, Świt P, Wach A,
Gołembiowska K (July 2019). "Hallucinogen-Like
Action of the
Novel Designer Drug 25I-NBOMe...
- PMID 11792466. S2CID 41740125. Chojnacka-Wójcik E, Tatarczyńska E,
Gołembiowska K, Przegaliński E (July 1991). "Involvement of 5-HT1A
receptors in the...
- doi:10.1021/acschemneuro.9b00528. PMC 9191638. PMID 31657895.
Wojtas A,
Gołembiowska K (December 2023). "Molecular and
Medical Aspects of Psychedelics". Int...
- the
original (PDF) on 2015-11-17.
Retrieved 2015-11-14.
Bymaster FP,
Golembiowska K,
Kowalska M, Choi YK,
Tarazi FI (June 2012). "Pharmacological characterization...
-
linearly to a
maximum of 348% at 240 min post-dosing.
Popik P,
Krawczyk M,
Golembiowska K,
Nowak G,
Janowsky A,
Skolnick P, et al. (2006). "Pharmacological profile...
- Study". ClinicalTrials.gov. 27
April 2007. Basile, AS; Janowsky, A;
Golembiowska, K; Kowalska, M; Tam, E; Benveniste, M; Popik, P; Nikiforuk, A; et al...
